1. Home
  2. NKTR vs NVCR Comparison

NKTR vs NVCR Comparison

Compare NKTR & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nektar Therapeutics

NKTR

Nektar Therapeutics

HOLD

Current Price

$60.25

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$16.68

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKTR
NVCR
Founded
1990
2000
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.0B
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
NKTR
NVCR
Price
$60.25
$16.68
Analyst Decision
Strong Buy
Buy
Analyst Count
7
6
Target Price
$146.67
$28.08
AVG Volume (30 Days)
555.7K
927.8K
Earning Date
05-07-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.79
EPS
N/A
N/A
Revenue
$307,711,000.00
$655,353,000.00
Revenue This Year
N/A
$7.72
Revenue Next Year
N/A
$6.74
P/E Ratio
N/A
N/A
Revenue Growth
86.00
8.28
52 Week Low
$33.40
$9.82
52 Week High
$109.00
$21.45

Technical Indicators

Market Signals
Indicator
NKTR
NVCR
Relative Strength Index (RSI) 38.09 48.96
Support Level $65.14 $16.33
Resistance Level $76.63 $18.43
Average True Range (ATR) 2.76 0.73
MACD -0.69 -0.02
Stochastic Oscillator 3.33 43.84

Price Performance

Historical Comparison
NKTR
NVCR

About NKTR Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Share on Social Networks: